Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aclarion Inc (ACON)

Aclarion Inc (ACON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,948
  • Shares Outstanding, K 671
  • Annual Sales, $ 50 K
  • Annual Income, $ -6,990 K
  • EBIT $ -7 M
  • EBITDA $ -6 M
  • 60-Month Beta 1.43
  • Price/Sales 89.61
  • Price/Cash Flow N/A
  • Price/Book 0.29

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -3.60
  • Number of Estimates 1
  • High Estimate -3.60
  • Low Estimate -3.60
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.36%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.55 +5.32%
on 11/26/25
8.09 -27.75%
on 12/04/25
-1.39 (-19.16%)
since 11/07/25
3-Month
5.55 +5.32%
on 11/26/25
12.03 -51.41%
on 10/13/25
-1.26 (-17.68%)
since 09/09/25
52-Week
5.55 +5.32%
on 11/26/25
3,499.51 -99.83%
on 01/03/25
-1,567.98 (-99.63%)
since 12/09/24

Most Recent Stories

More News
Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS)

Featured article strengthens growing body of clinical evidence for Nociscan by highlighting a successful case study Special Pain issue features breakthrough innovations shaping the future of spine...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Appoints Jason Brosniak as Commercial Director to Drive Adoption and Market Expansion in the Eastern U.S.

Proven commercial leader with 20+ years of experience driving revenue growth and market adoption for early-stage and high-growth MedTech companies Strong track record of launching breakthrough...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Wins “Rising Star” at 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Company previously announced it was selected as a finalist from more than 1,800 submissions Award win underscores growing impact of Aclarion’s breakthrough Nociscan solution for chronic low back...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted) providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89%...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Announces Use of MR Spectroscopy for identifying Biomarkers of Discogenic Pain highlighted at Global Neuroscience Conference

Panel discussion featured at the International Society of Pain and Neuroscience (ISPN) Annual Meeting in London titled United to Conquer Pain Session Co-Moderator Doug Beall, M.D. underscored that...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion to Present at the LD Micro Main Event XIX

Presentation on Monday, October 20, 2025 at 12:00 PM PTBroomfield, Colorado--(Newsfile Corp. - October 9, 2025) - Aclarion, Inc. (NASDAQ: ACON) (NASDAQ: ACONW) ("Aclarion" or the "Company"), a healthcare...

ACON : 5.81 (-1.19%)
Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

BROOMFIELD, Colo., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Presents at LSI Europe ’25 Highlighting Nociscan Technology and Key Value Drivers

BROOMFIELD, Colo., Oct. 01, 2025 (GLOBE NEWSWIRE) -- Aclarion, Inc ., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial

Enrollment remains on track with internal interim results expected in Q2 2026 Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan...

ACONW : 0.0421 (-12.11%)
ACON : 5.81 (-1.19%)
Aclarion Appoints Greg Gould as Chief Financial Officer

HealthTech CFO with extensive public company experience building organizations for growth and value creation Demonstrated success in raising capital, driving profitability, and scaling operations...

CWBHF : 0.0974 (-2.50%)
ACONW : 0.0421 (-12.11%)
CWEB.TO : 0.1350 (-3.57%)
ACON : 5.81 (-1.19%)

Business Summary

Aclarion Inc. is a healthcare technology company which leverages Magnetic Resonance Spectroscopy and a proprietary biomarker to optimize clinical treatments. The Company is also researching the application of AI and machine learning platforms to analyze both the raw spectroscopy data and the post-processed...

See More

Key Turning Points

3rd Resistance Point 6.78
2nd Resistance Point 6.59
1st Resistance Point 6.23
Last Price 5.81
1st Support Level 5.69
2nd Support Level 5.50
3rd Support Level 5.14

See More

52-Week High 3,499.51
Fibonacci 61.8% 2,164.82
Fibonacci 50% 1,752.53
Fibonacci 38.2% 1,340.24
Last Price 5.81
52-Week Low 5.55

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar